30 July 2016 in Radiation Oncology
The optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy is controversial. In particular, the prognostic significance of salvage radiotherapy delivered before a current definition of biochemical recurrence, i.e. ultra-early salvage radiotherapy, is unclear. We reviewed 76 patients with pT2-3N0M0 prostate cancer who underwent salvage radiotherapy for post-prostatectomy biochemical recurrence at the following three timings: ultra-early salvage radiotherapy (n = 20) delivered before meeting a current definition of biochemical recurrence (two consecutive prostate-specific antigen [PSA] values ≥0.2 ng/mL); early salvage radiotherapy (n = 40) delivered after meeting the definition but before PSA reached 0.5 ng/mL; and delayed salvage radiotherapy (n = 16) delivered after PSA reached 0.5 ng/mL. The primary endpoint was failure of salvage radiotherapy, defined as a PSA value ≥0.2 ng/mL. The log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses, respectively. During the follow-up period (median: 70 months), four of 20 (20 %), nine of 40 (23 %) and seven of 16 (44 %) patients failed biochemically in the ultra-early, early and delayed salvage radiotherapy groups, respectively. On univariate analyses, the outcome of delayed salvage radiotherapy was worse than the others, while there was no significant difference between ultra-early and early groups. Multivariate analysis demonstrated the presence of Gleason pattern 5, perineural invasion and delayed salvage radiotherapy as independent predictors of poorer survival. No survival benefit of ultra-early salvage radiotherapy was demonstrated, whereas delayed salvage radiotherapy was associated with worse outcome as reported in previous studies. Our results may support the current recommendations that salvage radiotherapy should be undertaken after two consecutive PSA values ≥0.2 ng/mL and before reaching 0.5 ng/mL.
1 December 2014 in Molecular and Clinical Oncology
This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration‑resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg̸m2 every 3 weeks combined with oral dexamethasone 1.0‑2.0 mg̸day between 2008 and 2013. The prostate‑specific antigen (PSA) level was monitored every 3 weeks. Chemotherapy was suspended when the serum PSA level decreased to 50% from the baseline. Treatment was resumed when serum PSA increased to >2 ng/ml, with an increase rate of >50% from the nadir. Of the 51 cases, 27 (52.9%) qualified for intermittent treatment; 17 patients received two courses of docetaxel chemotherapy and 10 received three courses. The median off‑treatment interval was 266 days for the first drug holiday, 129.5 days for the second and 146.5 days for the third. The multivariate analysis indicated low baseline PSA (<median, 30.55 ng̸ml; odds ratio = 0.059, P=0.010) and low Gleason score at diagnosis (≤7; odds ratio = 0.016, P=0.040) as significant factors for receiving intermittent therapy. The overall survival was better in intermittent cases (hazard ratio = 2.98 by log‑rank test, P=0.023). During the off‑treatment period, leukopenia, thrombopenia, appetite loss, diarrhea, alopecia, nail changes and fatigue subsided (0.0‑11.1%), whereas sensory and/or motor neuropathy persisted in 12 of the 27 cases (44.4%). Therefore, our intermittent regimen of docetaxel chemotherapy was found to be feasible for CRPC patients, since it may reduce adverse events without compromising the oncological outcome.
2 June 2017 in LUTS: Lower Urinary Tract Symptoms
20 July 2020 in The Japanese Journal of Urology
39歳男性,右鼠径部に腫瘤を自覚するも放置.人間ドックのPET-CTにて右鼠径部に被膜形成を伴う内部不均一な腫瘤(SUV max=1.48)を認め当院に紹介.造影MRIでは長径7 cmの概ね境界明瞭な脂肪性腫瘤で,陰茎根部外側の皮下に存在.内部は隔壁構造と造影効果を認めた.異型脂肪腫様腫瘍(いわゆる高分化型脂肪肉腫)疑いの診断で腫瘍摘除術施行.腫瘍は鼠径部皮下に存在,精索や陰茎海綿体は温存.摘出検体は13×7×3cm,肉眼的に黄色脂肪様だが淡い色調で軟らかい.病理組織学的には成熟脂肪細胞の増殖より成り,線維性の隔壁内に均一な紡錘形細胞が増殖.核分裂像や異型のある脂肪芽細胞は認めず.免疫組織化学では紡錘形細胞はCD34陽性,CDK4・MDM2陰性.以上よりSpindle cell lipomaと診断された.Spindle cell lipomaは脂肪腫の一亜型で,全脂肪性腫瘍の約1.5%と比較的稀な良性腫瘍である.肩や後頚部に好発し,鼠径部発生は非常に稀である.鼠径部発生の脂肪性腫瘍としては精索原発の異型脂肪腫様腫瘍(いわゆる高分化型脂肪肉腫)との鑑別が重要である.MRI所見は類似しており鑑別は困難だが,Spindle cell lipomaの多くは表在発生で皮下に位置する一方,異型脂肪腫様腫瘍は深部結合組織から発生し皮下組織には通常発生しない.以上より異型脂肪腫様腫瘍との術前鑑別は困難だが,皮下発生が多い点は鑑別の一助になる可能性があると考えられた.